Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.

ABSTRACT: Bevacizumab, a VEGF-targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma. We investigated this pattern using both a human specimen and rat models. In the human specimen, a substantial fraction of infiltrating tumor cells were located along perivascular spaces in close relationship with endothelial cells. Brain xenografts of U87MG cells treated with bevacizumab were smaller than controls (p = 0.0055; Student t-test), however, bands of tumor cells spread through the brain farther than controls (p < 0.001; Student t-test). Infiltrating tumor Cells exhibited tropism for vascular structures and propensity to form tubules and niches with endothelial cells. Molecularly, bevacizumab triggered an epithelial to mesenchymal transition with over-expression of the r

SUBMITTER: Falchetti ML 

PROVIDER: S-EPMC6590500 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature